Biotech Values

[DewDiligence]

3Q16 Harvoni vs Viekira* vs Zepatier ($ M)

[This is the same data as in #msg-126235931 with Epclusa removed;
the rationale for removing it that Epclusa is almost exclusively used
for GT2/GT3 patients, where Viekira is not approved.]

 
 Total  
 Harvoni         1860  77.4% 
 Viekira          378  15.7% 
 Zepatier         164   6.8% 
  
 US  
 Harvoni         1084  81.9% 
 Viekira           76   5.7% 
 Zepatier         164  12.4% 
  
 Ex-US  
 Harvoni          776  72.0% 
 Viekira          302  28.0%  
 Zepatier         n/a   n/a 

*Includes Viekirax/Technivie (2-DAA) brands.